嘉实中证疫苗与生物技术ETF(562860)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
22,629,963.55 |
-123,376,736.18 |
-144,625,740.51 |
-178,533,424.33 |
| 利息合计 |
5,793.32 |
177,165.32 |
168,659.20 |
824,115.44 |
| 其中：存款利息收入 |
5,793.32 |
17,958.64 |
9,452.52 |
615,443.52 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-25,650,179.40 |
-59,410,482.24 |
-28,746,074.15 |
-99,824,399.92 |
| 其中：股票投资收益 |
-27,260,408.65 |
-64,013,793.26 |
-31,139,399.51 |
-104,496,716.48 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
71,815.89 |
71,815.89 |
89,043.75 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
1,610,229.25 |
4,531,495.13 |
2,321,509.47 |
4,583,272.81 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
48,290,900.86 |
-64,275,919.00 |
-116,157,993.63 |
-79,212,234.99 |
| 其他收入 |
-16,551.23 |
132,499.74 |
109,668.07 |
-320,904.86 |
| 费用 |
878,266.91 |
2,184,708.39 |
1,209,183.37 |
4,061,198.60 |
| 管理人报酬 |
670,571.74 |
1,696,320.60 |
927,755.11 |
3,214,540.03 |
| 基金托管费 |
134,114.29 |
339,264.08 |
185,551.03 |
642,907.97 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
73,580.88 |
148,550.00 |
95,303.52 |
202,999.00 |
| 利润总额 |
21,751,696.64 |
-125,561,444.57 |
-145,834,923.88 |
-182,594,622.93 |
微信公众号
证券之星APP
基本资料
